Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

被引：0
|
作者：
R. de Haan
E. van Werkhoven
M.M. van den Heuvel
H. M. U. Peulen
G. S. Sonke
P. Elkhuizen
M. W. M. van den Brekel
M. E. T. Tesselaar
C. Vens
J. H. M. Schellens
B. van Triest
M. Verheij
机构：
[1] Department of Radiation Oncology,Department of Biometrics
[2] The Netherlands Cancer Institute,Department of Thoracic Oncology
[3] The Netherlands Cancer Institute,Department of Medical Oncology
[4] The Netherlands Cancer Institute,Department of Head and Neck Surgery and Oncology
[5] The Netherlands Cancer Institute,Division of Cell Biology
[6] The Netherlands Cancer Institute,Division of Pharmacology
[7] The Netherlands Cancer Institute,Department of Pharmaceutical Sciences
[8] The Netherlands Cancer Institute,undefined
[9] Utrecht University,undefined
来源：
BMC Cancer | / 19卷
关键词：
Radiotherapy; Radiosensitisation; Olaparib; PARP inhibitor; Phase 1; Dose escalation; TITE-CRM; Dose limiting toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.
    Molife, L. R.
    Forster, M. D.
    Krebs, M.
    Pwint, T.
    Middleton, M. R.
    Kaye, S. B.
    McCormack, P.
    Swaisland, H.
    Carmichael, J.
    Ranson, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
    Shapiro, Geoffrey I.
    Do, Khanh T.
    Tolaney, Sara M.
    Hilton, John F.
    Cleary, James M.
    Wolanski, Andrew
    Beardslee, Brian
    Hassinger, Faith
    Bhushan, Ketki
    Cai, Dongpo
    Downey, Elizabeth
    Pruitt-Thompson, Solida
    Barry, Suzanne M.
    Kochupurakkal, Bose
    Geradts, Joseph
    Unitt, Christine
    D'Andrea, Alan D.
    Muzikansky, Alona
    Piekarz, Richard
    Doyle, L. Austin
    Supko, Jeffrey
    CANCER RESEARCH, 2017, 77
  • [33] Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in triple negative breast cancer (TNBC) at low genetic risk (NCT00647062)
    Chiou, Victoria L.
    Kohn, Elise C.
    Annunziata, Christina M.
    Minasian, Lori
    Zujewski, JoAnne
    Yu, Minshu
    Ji, Jay
    Doroshow, James
    Gordon, Nicolas
    Houston, Nicole
    Lee, Jung-Min
    CANCER RESEARCH, 2014, 74 (19)
  • [34] Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
    Drew, Yvette
    Kim, Jae-Weon
    Penson, Richard T.
    O'Malley, David M.
    Parkinson, Christine
    Roxburgh, Patricia
    Plummer, Ruth
    Im, Seock-Ah
    Imbimbo, Martina
    Ferguson, Michelle
    Rosengarten, Ora
    Steeghs, Neeltje
    Kim, Min Hwan
    Gal-Yam, Einav
    Tsoref, Daliah
    Kim, Jae-Hoon
    You, Benoit
    De Jonge, Maja
    Lalisang, Roy
    Gort, Eelke
    Bastian, Sara
    Meyer, Kassondra
    Feeney, Laura
    Baker, Nigel
    Ah-See, Mei-Lin
    Domchek, Susan M.
    Banerjee, Susana
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 50 - 62
  • [35] Biomarkers of Histone Deacetylase Inhibitor Activity in a Phase 1 Combined-Modality Study with Radiotherapy
    Ree, Anne Hansen
    Saelen, Marie Gron
    Kalanxhi, Erta
    Ostensen, Ingrid H. G.
    Schee, Kristina
    Roe, Kathrine
    Abrahamsen, Torveig Weum
    Dueland, Svein
    Flatmark, Kjersti
    PLOS ONE, 2014, 9 (02):
  • [36] Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer
    Vidula, Neelima
    Horick, Nora
    Basile, Erin
    Blouch, Erica
    Ellisen, Leif W.
    Rugo, Hope S.
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [37] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ikeda, Masafumi
    Harano, Kenichi
    Matsubara, Nobuaki
    Toyoizumi, Shigeyuki
    Mori, Yuko
    Hori, Natsuki
    Nagasawa, Takashi
    Kogawa, Takahiro
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1568 - 1576
  • [38] Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
    Jens Samol
    Malcolm Ranson
    Edwina Scott
    Euan Macpherson
    James Carmichael
    Anne Thomas
    James Cassidy
    Investigational New Drugs, 2012, 30 : 1493 - 1500
  • [39] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Yoichi Naito
    Yasutoshi Kuboki
    Masafumi Ikeda
    Kenichi Harano
    Nobuaki Matsubara
    Shigeyuki Toyoizumi
    Yuko Mori
    Natsuki Hori
    Takashi Nagasawa
    Takahiro Kogawa
    Investigational New Drugs, 2021, 39 : 1568 - 1576
  • [40] Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC)
    Vidula, Neelima
    Damodaran, Senthil
    Bhave, Manali A.
    Rugo, Hope S.
    Blouch, Erica
    Ruffle-Deignan, Nathan Royce
    Shah, Ami N.
    Cristofanilli, Massimo
    Abramson, Vandana G.
    Sparano, Joseph A.
    Ostrer, Harry
    Horick, Nora K.
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345